Serum total bilirubin =< twice the institutional upper limit of normal (ULN) within 21 days of registration on study (or within 21 days prior to day 1 of chemotherapy post-surgery for those patients having started chemotherapy prior to first step registration)
545.0
Total bilirubin within institutional upper limit of normal (IULN)
162.0
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Total bilirubin =< IULN
162.0
Serum creatinine =< 2 x institutional upper limit of normal (IULN), unless due to lymphoma, within 42 day prior to registration
155.0
Total bilirubin =< 2 x institutional upper limit of normal (IULN) (unless due to Gilbert syndrome) within 42 days prior to registration
155.0
Within 14 days prior to registration: Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)
130.0
Patients must have bilirubin =< 2 x IULN within 7 days prior to registration (unless the bilirubin is primarily unconjugated)
38.0
Serum bilirubin =< institutional upper limit of normal (IULN) within 28 days prior to sub-study registration; for patients with liver metastases, bilirubin must be =< 5 x IULN
10000.0
Total bilirubin =<1.5 x institutional upper limit of normal (IULN)
35.0
Patients must have total bilirubin =< 2.0 x IULN within 14 days prior to registration
44.0
AST and ALT =< 3.0 x institutional upper limit of normal (IULN) within 14 days prior to registration
44.0
Total bilirubin =< 2.0 x IULN within 14 days prior to registration
44.0
Registration Step 3 � Maintenance: Patients must have AST and ALT =< 3.0 x institutional upper limit of normal (IULN) within 14 days prior to registration
44.0
Registration Step 3 � Maintenance: Patients must have total bilirubin < 2.0 x institutional upper limit of normal (IULN) within 14 days prior to registration
44.0
Obtained within 28 days prior to registration: Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)
223.0
Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)
150.0
Within 14 days prior to registration: Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)
143.0
CLINICAL/LABORATORY CRITERIA: Total bilirubin =< 1.5 x institutional upper limit of normal (IULN); these results must be obtained within 28 days prior to registration
53.0
Obtained within 28 days prior to registration: Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (or =< 3.0 x IULN with Gilbert's syndrome)
77.0
Within 28 days prior to registration: Total bilirubin =< 2.0 x institutional upper limit of normal (IULN) or for documented/suspected Gilbert�s disease, total bilirubin =< 3.0 x IULN
707.0
Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except Gilbert�s syndrome, who must have a total bilirubin < 3.0 mg/dL), obtained within 28 days prior to step 2 registration
1000.0
Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) except patients with documented Gilbert�s syndrome within 28 days prior to registration
64.0
Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (=< 5 x IULN if secondary to lymphoma, Gilbert�s syndrome, or medication related [e.g., indinavir, tenofovir, atazanavir]) within 28 days prior to registration
150.0
Direct bilirubin =< 1.5 x IULN (=< 5 x IULN if secondary to lymphoma) within 28 days prior to registration
150.0
Total bilirubin =< 2.5 x institutional upper limit of normal (IULN) (except patients with Gilbert�s syndrome) within 28 days prior to registration
94.0
Total bilirubin =< 1.5 x upper limit of normal (ULN)
729.0
Total bilirubin =< 1.5 x the upper limit of normal (ULN)
102.0
Total bilirubin < 2 x institutional upper limit of normal (ULN)
700.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) obtained =< 21 days prior to registration
360.0
Total serum bilirubin =< 1.5 times upper limit of normal (ULN) (=< grade 1); if total bilirubin is 2 to 3 mg/dL, but direct bilirubin is normal, then the patient will be considered eligible
747.0
Bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (CTCAE grade 1)
128.0
Total bilirubin =< 5 x upper limit of normal (ULN)
276.0
Total bilirubin < 1.5 x upper limit of normal assessed within seven (7) days prior to the start of therapy
30.0
Bilirubin =< 3.0 x upper limit of normal (ULN)
48.0
Total bilirubin =< 1.5 x upper limit of normal (ULN)
1120.0
TREATMENT: Bilirubin =< 2 x upper limit of normal
44.0
Bilirubin < 1.5 times institutional upper limit of normal, within 21 days prior to study entry
143.0
Total bilirubin =< 1.5 institutional upper limit of normal (ULN)
110.0
Obtained =< 7 days prior to registration: Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
102.0
Serum bilirubin > 1.5 x upper limit of normal (ULN)
45.0
Total bilirubin =< 1.5 times upper limit of normal (ULN)
55.0
Total bilirubin < 2 x the institutional upper limit of normal (ULN)
252.0
Total bilirubin < 2 x institutional upper limit of normal (ULN) within 14 days prior to registration
660.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
140.0
Total bilirubin =< 1.5 x upper limit of normal (ULN)
72.0
Bilirubin < 1.5 x upper limit of normal (ULN)
80.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
30.0
Total bilirubin =< 1.5 within 30 days prior to registration* It is highly recommended but not required that total bilirubin be =< 1.5 upper limit of normal
330.0
Total bilirubin =< 1.5 x upper limit of normal (ULN)
92.0
Bilirubin less than or equal to 1.5 x institutional/laboratory upper limit of normal (ULN)
540.0
Bilirubin =< 1.5 times upper limit of normal
250.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN), within 21 days prior to registration
924.0
Bilirubin =< 1.5 x upper limit of normal (ULN)
20.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
24.0
Total bilirubin > 2 times the upper limit of normal
125.0
Total bilirubin =< 1.5 x upper limit of normal (ULN)
40.0
Bilirubin =< 1.5 upper limit of normal (ULN)
606.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
35.0
Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (or =< 2.5 x upper limit of normal [ULN] with Gilbert�s syndrome)
280.0
Total bilirubin =< 1.5 x upper limit of normal (ULN)
450.0
Total bilirubin =< 1.5 x upper limit of normal (ULN)
90.0
Total bilirubin =< 1.5 x upper limit of normal (ULN)
42.0
Total bilirubin =< 1.5 times institutional upper limit of normal (ULN)
110.0
INCLUSION CRITERIA FOR STRATUM C: Total bilirubin =< 1.5 times institutional upper limit of normal (ULN)
110.0
Total bilirubin =< 1.5 � upper limit of normal (ULN) for the laboratory unless resulting from hemolysis
30.0
Total bilirubin =< institutional upper limit of normal (ULN) or =< 1.5 X institutional ULN (if the patient has liver metastases)
126.0
Total bilirubin within =< 1.5 times the upper limit of normal (ULN) institutional limits
680.0
Total bilirubin less than or equal to the institution's upper limit of normal
33.0
Total bilirubin =< 1.5 x the institutional upper limit of normal (ULN)
126.0
Total bilirubin < 1.5 upper limit of normal (ULN)
46.0
Total bilirubin =< 1.5 x upper limit of normal (ULN)
45.0
Total bilirubin =< the upper limit of normal (ULN) within 4 weeks prior to randomization
345.0
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Total bilirubin =< 1.5 times institutional upper limit of normal (ULN)
50.0
NON-PROGRESSED DIPG (STRATUM 2): Total bilirubin =< 1.5 times institutional upper limit of normal (ULN)
50.0
Total bilirubin below normal institutional upper limit of normal (ULN)
48.0
Bilirubin =< 1.5 x upper limit of normal (ULN), within 14 days prior to registration
147.0
Total bilirubin =< 1.5 times institutional upper limit of normal (ULN)
25.0
Within 28 days prior to administration of study treatment: Total bilirubin =< 1.5 x the institutional upper limit of normal (ULN)
90.0
Within less than or equal to 14 days prior to registration: Total serum bilirubin =< institutional upper limit of normal (ULN)
40.0
Within 28 days prior to administration of therapy: Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
132.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
40.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
70.0
Total bilirubin < 4 x institutional upper limit of normal (ULN)
186.0
Bilirubin =< 1.5 upper limit of normal (ULN)
120.0
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
77.0
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
154.0
Patients on Part A and Part B: bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
148.0
Patients on Part C with ALL: bilirubin (sum of conjugated + unconjugated) =< 1.5 x ULN for age
148.0
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
484.0
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
67.0
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
65.0
Bilirubin (sum of conjugated + conjugated) =< 1.5 x upper limit of normal (ULN) for age
36.0
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
51.0
Patients with solid tumors: bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
49.0
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
98.0
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
49.0
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
49.0
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
144.0
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age within 7 days prior to enrollment
49.0
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
1500.0
Bilirubin =< 1.5 x normal
360.0
Total bilirubin within =< 1.5 normal institutional limits (patients with Gilbert�s syndrome with total bilirubin up to 2.5 mg/dL is allowed)
74.0
Obtained within 30 days of registration: Total bilirubin within normal institutional limits (may be elevated if direct bilirubin normal)
24.0
Bilirubin within normal institutional limits within 14 days prior to registration
234.0
Total bilirubin < 1.5 x upper limits of normal (ULN)
2060.0
Total serum bilirubin within normal institutional limits
70.0
Total bilirubin < 1.5 x upper limits of normal (ULN)
97.0
RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Total bilirubin < 1.5 x upper limits of normal (ULN)
97.0
Total bilirubin within normal institutional limits
12.0
Total bilirubin =< 1.5 x upper limits of normal (ULN)
34.0
Total bilirubin < 1.5 x institutional upper limit of normal with direct bilirubin within normal limits except for participants with Gilbert�s disease
23.0
Total bilirubin within institutional normal limits (or < 2.5 X the ULN for patients with Gilbert�s disease)
60.0
Total bilirubin within normal institutional limits
12.0
Total bilirubin within normal institutional limits
209.0
Total bilirubin within normal institutional limits
30.0
Total bilirubin within normal institutional limits
30.0
Total bilirubin within normal institutional limits
15.0
Total bilirubin within normal institutional limits
46.0
Total bilirubin within normal institutional limits
45.0
Serum bilirubin =< 2.5 times ULN except for participants who are on atazanavir or indinavir, provided that the participant�s direct bilirubin is within normal institutional limits
18.0
Within 2 weeks prior to initiation of study treatment: Total bilirubin within normal institutional limits
70.0
Total bilirubin within normal institutional limits
51.0
Total bilirubin within normal institutional limits
150.0
Total bilirubin within normal institutional limits
20.0
Total bilirubin: within normal limits at each study site local laboratory
36.0
Total bilirubin within normal institutional limits
38.0
Total bilirubin within normal institutional limits
70.0
Total bilirubin within normal institutional limits
40.0
Bilirubin within institutional normal limits
50.0
Total bilirubin < 1.5 x upper limit of normal (ULN) for age
400.0
Total bilirubin < 1.5 x upper limit of normal (ULN) for age
253.0
Total bilirubin < 1.5 x upper limit of normal (ULN) for age
693.0
Total bilirubin =< 1.5 times upper limit of normal (ULN) for age
275.0
Total bilirubin =< 1.5 x upper limit of normal for age
62.0
Total bilirubin =< 1.5 x ULN for age AND
74.0
Total bilirubin < 1.5 times upper limit of normal for age, within 14 days of registration and within 7 days of the start of treatment
180.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
140.0
Total bilirubin =< 1.5 times upper limit of institutional normal (ULN) for age
40.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
600.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
340.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and
330.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
81.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
90.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
44.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
337.0
Direct bilirubin < 1.5 x upper limit of normal (ULN) for age and institution
56.0
Total or direct bilirubin =< 1.5 x upper limit of normal (ULN) for age, and
45.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
146.0
Direct bilirubin =< 1.5 x upper limit of normal (ULN) for age, and
53.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
1680.0
Bilirubin =< 1.5 x ULN (CTCAE v 3.0 grade 1)
164.0
Bilirubin =< 1.5 x ULN
36.0
Patients must have a total serum bilirubin =< 1.5 x ULN (grade =< 1) and a serum creatinine =< grade 1
747.0
Patients with abnormal liver function will be eligible and will be grouped according to the criteria below* Group A (normal hepatic function)** Bilirubin =< upper limit of normal (ULN) and aspartate aminotransferase (AST) =< ULN* Group B (mild hepatic dysfunction)** B1: bilirubin =< ULN and AST > ULN** B2: bilirubin > ULN but =< 1.5 x ULN and any AST* Group C (moderate hepatic dysfunction)** Bilirubin > 1.5 x ULN to =< 3 x ULN and any AST* Group D (severe hepatic dysfunction) ** Bilirubin > 3 x ULN and up to investigators discretion and any AST* Patients with active hemolysis should be excluded; no distinction will be made between liver dysfunction due to metastases and liver dysfunction due to other causes; registration laboratory investigations will be used to assign a patient to a hepatic function group; liver function tests should be repeated within 24 hours prior to starting initial therapy and may result in the patients' group assignment being altered if different to registration test results
132.0
Bilirubin =< 1.5 x ULN
52.0
Total bilirubin =< 2.0, within 30 days prior to enrollment
278.0
Patients with abnormal hepatic function will be eligible and will be grouped according to criteria summarized below:* Group A: Normal hepatic function** Bilirubin =< ULN** Aspartate aminotransferase (AST) =< ULN* Group B: Mild hepatic dysfunction** B1: bilirubin =< ULN and AST > ULN** B2: ULN < bilirubin =< 1.5 x ULN and any AST* Group C: Moderate hepatic dysfunction** 1.5 x ULN < bilirubin =< 3 x ULN and any AST* Group D: Severe hepatic dysfunction** 3 x ULN < bilirubin =< 10 x ULN and any AST; hepatic function tests should be repeated within 24 hours prior to starting initial therapy and may result in patients� group assignment being altered if different to registration test results
68.0
Bilirubin =< 1.5 x ULN; for subjects with liver metastases =< 3 x ULN is allowed
30.0
Total serum bilirubin =< 1.5 x ULN
NONE
Serum total bilirubin =< 1.5 X upper limit of normal (ULN) or direct bilirubin =< ULN for patients with total bilirubin levels > 1.5 ULN
36.0
Total bilirubin < 1.5 x ULN
58.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) in absence of Gilbert disease (total bilirubin =< 3 x ULN with Gilbert); also, if hyperbilirubinemia is clearly attributed to liver metastases total bilirubin =< 3 x ULN is permitted
195.0
Re-registration: total bilirubin =< 1.5 x ULN in absence of Gilbert disease (total bilirubin =< 3 x ULN with Gilbert); if hyperbilirubinemia is clearly attributed to liver metastases, total bilirubin =< 3 x ULN is permitted
195.0
Total bilirubin =< 1.5 x ULN
23.0
Total bilirubin =< 1.5 x the institutional ULN
549.0
If no known liver metastases: total bilirubin < 1.5 x institutional upper limit of normal (ULN); if known liver metastases, then: total bilirubin < 2.5 x ULN
46.0
Total serum bilirubin =< 1.5 x ULN (in patients with known Gilbert syndrome, a total bilirubin =< 3.0 x ULN, with direct bilirubin =< 1.5 x ULN)
64.0
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 x ULN), within 4 weeks of randomization
766.0
Serum total bilirubin: =< 1.5 X ULN OR
56.0
Direct bilirubin: =< ULN for patients with total bilirubin levels > 1.5 ULN
56.0
Total bilirubin =< 1.5 x ULN within 14 days prior to registration.
186.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled)
35.0
Within 14 days prior to registration: Total Bilirubin =< 1.5 x ULN (patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled)
488.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled)
72.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled)
40.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled)
60.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled)
22.0
Total bilirubin:* If no known liver metastases: total bilirubin < 1.5 x institutional upper limit of normal (ULN)* If known liver metastases, then: total bilirubin < 2.5 x ULN
47.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled)
78.0
Bilirubin* =< 2 x upper limit of normal* In the absence of Gilbert�s disease
100.0
Total bilirubin =< 1.5 times the institutional upper limit of normal (ULN), unless elevated secondary to lymphomatous involvement of liver or biliary system, or due to other HIV medications (e.g., indinavir, tenofovir, or atazanavir); if secondary to lymphomatous involvement, an initial upper limit of total bilirubin 5 mg/dL (85.5 uM/L) should be utilized - for direct bilirubin > 1.2 mg/dL (20.5 uM/L)
90.0
Total bilirubin must be < 1.5 x the upper limit of normal, unless the elevation of bilirubin is thought to be secondary to Gilbert�s syndrome or combined antiretroviral therapy (cART); if, however, the elevated bilirubin is felt to be secondary to antiretroviral therapy, the total bilirubin must be =< 3.5 mg/dL, provided that the direct bilirubin is normal and the aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x the upper limit of normal; also, if the elevated bilirubin is thought to be secondary to cHL the same criteria for hyperbilirubinemia should be applied; however 1 prior cycle of cyclophosphamide is permitted in attempt to make the participant eligible; patients should not be excluded from study participation unless dosing cannot be safely established
70.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (unless due to Gilbert�s disease or disease-related hemolysis, then =< 3.0 x ULN)
113.0
Total bilirubin=< 1.5 x upper limit of normal (ULN) (if, however, the participant has Gilbert�s disease or unconjugated hyperbilirubinemia that is considered to be secondary to with atazanavir or indinavir therapy, then the total bilirubin must be =< 3 x ULN)
42.0
Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert�s syndrome, for which bilirubin =< 3 x upper limit of normal [ULN] is permitted) obtained within 2 weeks prior to registration
189.0
RANDOMIZED PHASE II (ARMS K AND L): Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert�s syndrome, for which Bilirubin =< 3 x upper limit of normal [ULN] is permitted); obtained within 2 weeks prior to registration
189.0
Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (or =< 2.5 x ULN for patients with Gilbert�s syndrome)
97.0
Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN) except subjects with known Gilbert�s syndrome
40.0
Bilirubin =< 1.5 x institutional upper limit of normal (ULN) except subjects with known Gilbert�s syndrome, within 2 weeks of the first dose of study treatment
18.0
Direct or total bilirubin < 1.5 x ULN (unless related to Gilbert�s or Meulengracht�s syndrome); the values must be obtained within 48 hours prior to randomization
509.0
Total bilirubin < 2.0 mg/dL unless due to Gilbert�s disease, hemolysis or leukemia
63.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (patients with Gilbert�s syndrome may have serum bilirubin > 1.5 � ULN)
130.0
Bilirubin =< 1.5 x ULN within 14 days prior to study registration; unless patient has Gilbert�s disease
440.0
Total bilirubin =< 1.5 x institutional upper limit of normal; unless due to Gilbert�s syndrome
100.0
Total bilirubin =< ULN (institutional upper limit of normal) except elevated total bilirubin < 1.5 x ULN due to Gilbert�s disease or similar syndrome involving slow conjugation of bilirubin, measured within 28 days prior to randomization
1500.0
Total bilirubin < 1.5 x institutional upper limit of normal (=< 3 mg/dL in case of Gilbert�s syndrome)
600.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (or =< 2.5 x ULN with Gilbert�s disease)
230.0
Total bilirubin =< 1.5 x ULN (institutional upper limit of normal) (patients with Gilbert�s syndrome may have direct bilirubin > 2.5 x ULN)
44.0
Total bilirubin =< 1.5 x ULN except subjects with normal direct bilirubin or those with known Gilbert�s syndrome, obtained within 4 weeks prior to randomization
300.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) (unless Gilbert�s syndrome or disease infiltration of the liver is present)
52.0
Bilirubin =< 1.5 x ULN upper limit of normal (except in patients with documented Gilbert�s disease, who must have a total bilirubin =< 3.0 mg/dL), must be obtained within 8 weeks prior to screening for protocol therapy
562.0
ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Bilirubin =< 1.5 x ULN (except in patients with documented Gilbert�s disease, who must have a total bilirubin =< 3.0 mg/dL)
562.0
Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN) except subjects with known Gilbert�s syndrome
18.0
Total bilirubin =< 1.5 x upper limit of normal (ULN); for subjects with known Gilbert�s disease or similar syndrome with slow conjugation of bilirubin, total bilirubin =< 3.0 mg/dL
135.0
Total bilirubin =< 1.25 x institutional upper limit of normal (ULN), with the exception of < 2.9 mg/dL for patients with Gilbert�s disease
66.0
Total bilirubin =< 1.5 x ULN except subjects with normal direct bilirubin or those with known Gilbert�s syndrome
400.0
Within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration: Total bilirubin =< 1.5 X institutional upper limit of normal (ULN) (unless documented Gilbert�s syndrome, for which bilirubin =< 3 x institutional ULN is permitted)
6452.0
Within 6 weeks prior to randomization: Total bilirubin must be =< upper limit of normal (ULN) for the laboratory (lab) unless the patient has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert�s disease or similar syndrome involving slow conjugation of bilirubin
990.0
PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) =< 3 x ULN for subjects with Gilbert�s disease or with atazanavir- or indinavir-induced unconjugated hyperbilirubinemia without aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation and must have a total bilirubin less than 3.0 mg/dL, within 2 weeks prior to enrollment
84.0
PARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Total bilirubin: =<1.5 � institutional upper limit of normal (ULN), or =< 3 x ULN for participants with Gilbert�s disease or with atazanavir- or indinavir-induced unconjugated hyperbilirubinemia without AST or ALT elevation, and must have a total bilirubin less than 3.0 mg/dL), within 2 weeks prior to enrollment
84.0
Total bilirubin =< 1.5 x upper limit of normal (ULN); except in case of Gilbert�s disease
69.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) unless isolated hyperbilirubinemia attributed to Gilbert�s syndrome
302.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN); an exception to this may be allowed for participants with Gilbert�s syndrome with documented approval by the protocol chair
45.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) (patients with Gilbert�s syndrome may have serum bilirubin > 1.5 ULN)
82.0
Total bilirubin =< 1.5 x ULN (patients with Gilbert�s syndrome may have serum bilirubin > 1.5 x ULN)
50.0
Total bilirubin =< 1.5 x upper limit of normal (ULN), unless due to Gilbert�s syndrome or hemolysis, in which case =< 3.0 x ULN is allowed
50.0
Total bilirubin =< 1.5 x ULN unless Gilbert�s syndrome of disease infiltration of the liver is present
32.0
Total bilirubin < 1.5 X upper limit of normal (ULN); or < 3 x institutional ULN for Gilbert�s syndrome or HIV protease inhibitors; or < 5 x ULN and direct bilirubin < 0.7 mg/dL for patients on atazanavir containing HIV regimen
60.0
Total bilirubin must be =< ULN (upper limit of normal) for the lab unless the patient has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert�s disease or similar syndrome involving slow conjugation of bilirubin within 28 days before randomization
348.0
Total bilirubin (=< 1.5 mg/dl) normal unless history of Gilbert�s syndrome
612.0
Total bilirubin =< 1.5 x normal institutional limits; this will not apply to patients with confirmed Gilbert�s syndrome (persistent or recurrent hyperbilirubinemia [predominantly unconjugated bilirubin] in the absence of evidence of hemolysis or hepatic pathology), who will be allowed in consultation with their physician
180.0
Total bilirubin =< 1.5 x local institutional upper limit of normal (ULN)* If elevated total bilirubin is due Gilbert�s disease or disease-related hemolysis then total bilirubin =< 3.0 x local institutional ULN
48.0
Total bilirubin =< 2.0 mg/dL unless due to Gilbert�s syndrome, hemolysis, or ineffective hematopoiesis
27.0
Total bilirubin > 1.5 times ULN if no liver metastases or > 3 times ULN in the presence of documented Gilbert�s syndrome (unconjugated hyperbilirubinemia) or liver metastases
98.0
Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert�s syndrome, who can have total bilirubin < 3 mg/DL)
21.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN), (except for patients with known Gilbert�s syndrome who must have normal direct bilirubin)
30.0
Direct bilirubin =< 3 x upper limit of normal (ULN), unless suspected leukemic involvement of the liver
324.0
Total bilirubin =< 1.5 x upper limit of normal (ULN), except for patients with known Gilbert�s syndrome
324.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) within 30 days of day 1 of study; NOTE: patients with elevated bilirubin secondary to Gilbert�s disease are eligible to participate in the study
27.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN); =< 3 x institutional ULN if the patient has Gilbert's syndrome
40.0
Bilirubin within 1.5 x the upper limit of normal for age, with the exception of those with Gilbert syndrome
104.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
80.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
37.0
Bilirubin =< 1.5 x ULN; for patients with Gilbert's syndrome, bilirubin =< 3.0 mg/dL is acceptable
96.0
Total bilirubin =< 1.5 upper limit of normal (ULN), with the exception of patients with Gilbert syndrome
50.0
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
29.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) (except in subjects with Gilbert syndrome who must have a total bilirubin < 3.0 x ULN)
714.0
Total bilirubin =< 1.5 x upper limit of normal (ULN); unless patient has Gilbert disease
137.0
Bilirubin =< 1.5 x ULN (=< 3 x ULN for patients with Gilbert syndrome)
84.0
Total bilirubin =< 1.5 X upper limit of normal (ULN), with exception of patients with Gilbert syndrome
24.0
Total bilirubin =< 1.5 X upper limit of normal (ULN), with the exception of patients with Gilbert syndrome who are required to have =< 3 X ULN
24.0
Total bilirubin < 1.5 x institutional upper limit of normal (with the exception of those with Gilbert syndrome
28.0
Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL)
148.0
Total bilirubin =< 1.5 x upper limit of normal (ULN) except in the case of Gilbert disease
700.0
Serum total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (patients with Gilbert's syndrome with a total bilirubin < 3.0 mg/dL)
68.0
Total bilirubin =< 2 x institutional upper limit of normal
107.0
Total bilirubin < 1.5 x institutional upper limit of normal
165.0
Total bilirubin =< institutional upper limit of normal
36.0
Total bilirubin =< 1.5 X institutional upper limit of normal
68.0
Total bilirubin < 1.5 X institutional upper limit of normal
73.0
Total bilirubin within =< 1.5 x institutional upper limit of normal
72.0
Total bilirubin =< 1.5 x institutional upper limit of normal
72.0
TUMOR BIOPSY SEQUENCING: Total bilirubin < 1.5 x institutional upper limit of normal
700.0
TREATMENT: Total bilirubin < 1.5 x institutional upper limit of normal
700.0
Total bilirubin =< x 1.5 upper limit of institutional normal
52.0
Total bilirubin =< 1.5 x institutional upper limit of normal OR > 1.5 x institutional upper limit of normal allowed if direct bilirubin is within normal range
68.0
Total bilirubin =< 1.5 x institutional upper limit of normal
54.0
Total bilirubin < 1.5 x institutional upper limit of normal OR > 1.5 x institutional upper limit of normal allowed if direct bilirubin is within normal range
32.0
Total bilirubin =< 1.5 x institutional upper limit of normal
57.0
Total bilirubin =< institutional upper limit of normal
23.0
Total bilirubin =< 1.5 x institutional upper limit of normal
35.0
Total bilirubin =< institutional upper limit of normal
75.0
Total bilirubin =< 1.5 x institutional upper limit of normal
46.0
Total bilirubin =< 1.5 x institutional upper limit of normal
35.0
Total bilirubin =< 1.5 X institutional upper limit of normal
37.0
Total bilirubin =< 1.5 institutional upper limit of normal
36.0
Total bilirubin =< 1.5 x institutional upper limit of normal
36.0
Total bilirubin within institutional upper limit of normal
90.0
Total bilirubin =< 1.5 X institutional upper limit of normal
60.0
Total bilirubin =< institutional upper limit of normal
35.0
Bilirubin < 1.5 mg/dl
348.0
If the patient is to be treated with cisplatin, the serum bilirubin of =< 2.0 mg%
37.0
Total bilirubin =< grade 1* Note: If total bilirubin is 2 to 3 mg/dL, but direct bilirubin is normal, then the patient will be considered eligible
747.0
Total serum bilirubin =< 1.5 x ULN* NOTE: if total bilirubin is 2-3 mg/dL, but direct bilirubin is normal, then the patient will be considered eligible
747.0
Bilirubin =< grade 1* If bilirubin is 2-3 mg/dL, but direct bilirubin is normal then patient will be considered eligible
747.0
Total bilirubin < 1.5 mg/dl
130.0
Bilirubin =< 1.5 mg/dL (or =< 3.0 mg/dL if due to Gilbert's syndrome) within 28 days prior to registration
1900.0
Serum bilirubin =< 2.0 mg/dL within 28 days prior to registration
491.0
Direct bilirubin =< 1 mg/dL
42.0
Serum direct bilirubin < 2 mg/dl or serum total bilirubin =< 3; NOTE: the above stipulation for normal hepatic function does not apply if liver dysfunction is due to leukemia infiltration
509.0
Obtained =< 48 hours prior to registration: Serum direct bilirubin < 2 mg/dL or serum total bilirubin =< 3
509.0
Direct bilirubin < 3.0 mg/dL
598.0
Total bilirubin < 1.5 mg/dL
28.0
Total bilirubin < 2.5 mg/dl
182.0
Total bilirubin < 2.0 mg/dL
188.0
Bilirubin =< 2.0 mg/dL
130.0
Bilirubin =< 1.5 mg/dL (or =< 3.0 mg/dL if due to Gilbert's syndrome or if liver metastases are present)
333.0
Total bilirubin =< 2.0 mg/dL
124.0
Total bilirubin =< 2.0 mg/dL (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
30.0
Direct bilirubin =< 2.0 mg/dL
700.0
